Skip to main content
Rapid Dose Therapeutics Corp logo

Rapid Dose Therapeutics Corp — Investor Relations & Filings

Ticker · DOSE ISIN · CA75339A1012 CSE Manufacturing
Open in API
Filings indexed 490 across all filing types
Latest filing 2023-07-26 Regulatory Filings
Country CA Canada
Listing CSE DOSE

About Rapid Dose Therapeutics Corp

https://rapid-dose.com/

Rapid Dose Therapeutics Corp. is a pharma-technology company specializing in proprietary drug delivery technologies engineered to enhance patient outcomes and quality of life. The core business revolves around an innovative oral delivery platform utilizing sublingual thin film strip technology. The company's flagship product, QuickStrip™, is a fast-dissolving system designed for the rapid release of pharmaceuticals, micronized oils, and over-the-counter medicines. QuickStrip™ is distinguished by its ability to achieve blood concentrations comparable to intravenous injection, offering superior bioavailability and rapid onset. RDT provides product innovation, production, and consultation services to the pharmaceutical and healthcare manufacturing sectors for both prescription and non-prescription applications.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings
2023-07-26 English
News release - English.pdf
Regulatory Filings
2023-07-26 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a corporate update from Rapid Dose Therapeutics Corp. dated July 7, 2023. It provides detailed information about the company's business segments, product launches, collaborations, market opportunities, and recent corporate developments such as a new director joining the board and a $5.0M convertible note financing. The document also mentions the upcoming Annual General and Special Meeting of shareholders scheduled for August 1, 2023. The content is focused on business progress, strategic initiatives, and financing updates rather than financial statements or regulatory filings. It is not a full annual or interim report, audit report, earnings release, or legal proceeding update. The presence of a new director announcement and financing update suggests it is a corporate update. Given the detailed nature of the business and financing information, the most appropriate classification is Capital/Financing Update (CAP).
2023-07-07 English
Form of proxy - English.pdf
Regulatory Filings
2023-07-07 English
Audited annual financial statements (amended) - English.pdf
Annual Report Classification · 100% confidence The document contains consolidated financial statements for Rapid Dose Therapeutics Corp. for the years ended February 28, 2023 and 2022. It includes an Independent Auditor's Report, Management's Responsibility for Financial Reporting, detailed financial statements such as Statements of Financial Position, Statements of Loss and Comprehensive Loss, Statements of Changes in Shareholders' Equity, Statements of Cash Flows, and Notes to the Financial Statements. The presence of a full set of audited financial statements and the auditor's opinion indicates this is a comprehensive annual report. The document length is substantial (15,000 characters), and it is not merely an announcement or certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2023
2023-06-29 English
52-109FV1 - Certification of annual filings - CEO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a FORM 52-109FV1 Certification of Annual Filings Venture Issuer Basic Certificate signed by the CEO. It certifies the review and fair presentation of annual filings for the financial period ended February 28, 2023. The document is a certification letter and does not contain actual financial statements or substantive financial data. It explicitly states it is a certificate and includes disclaimers about controls and procedures. The document length is 3133 characters, which is relatively short and consistent with a certification letter rather than a full report. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS) rather than as the actual annual report or interim report. Therefore, the correct classification is Regulatory Filings (RNS).
2023-06-29 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.